Alzamend Neuro is trading 6.2% down at $1.50 in after-hours trading, with potential resale shares issuable upon preferred-stock conversion creating a possible dilution overhang.
- No new company-specific announcement clearly explains the decline.
- The latest notable filing registered the potential resale shares.
- Shares closed at $1.60 on August 25, 2026; the broader market was higher.